|Dr. Nathan Xin Zhang|
|Dr. Jerry Li|
|Dr. Yi Lin|
|Ting Zhao|
|Wang Weidong|
 
 
About Management Teams



Dr. Nathan Xin Zhang

Dr. Zhang was C.E.O. of China Chipscreen Bioscience from 2001 to 2004 and built Chipscreen into the largest R&D based Biotech Company focusing on discovery of novel small molecules of diabetes and cancer drug in China. Chipscreen started with 6 Million USD venture fund in 2001. By 2002, Chipscreen had been recognized as one of the Ten Companies To Watch in the Asia Pacific region at the Asia Pacific Biotech and Pharmaceutical summit of 2002. Chipscreens diabetes and cancer lead compounds (HDAC inhibitor) will go into phase I clinical studies this year.

Prior to joining Chipscreen, Dr. Zhang was Managing Director at Delirium, a New York based International company. He also worked as a senior consultant at KPMG LLP's Healthcare consulting business in New York, served at the Credit Suisse First Boston's investment banking group in New York, and was a scientific co-founder of CDR Therapeutics, Inc., a Seattle-based bio-pharmaceutical startup company, which raised 6 million USD in 1995. Dr. Zhang was recipient of Brupbacher Young Investigator Award from Charles Rudolph Brupbacher Foundation in Switzerland and James A. McLaughlin Award from American National Student Research Forum during his PHD study period in USA.

China Medicine Economic News recognized Dr. Zhang as one of Chinas New Strength, Top Individuals of China Pharmaceutical Industry in 2003. Dr. Zhang was the co-organizer of China panel discussion at Bio2004 in San Francisco, and US-China pharmaceutical and Biotech conference in New York. Dr. Zhang was invited speaker at Harvard China Review 2004 Conference, Wharton China Business Forum 2004, Sachs Bloomberg Global Biotech and Pharmaceutical Investment Forum in Boston, and IBC conference series on the topic of current and future development of Chinese biotech and pharmaceutical industry.

Dr. Zhang received his Ph.D. in pharmacology from Medical School of University of Pennsylvania, M.D. from Tianjin Medical University's Eight Year Program, and MBA from University of Chicago with a concentration in Finance and Accounting.


Dr. Jerry Li

Dr. Jerry Li was founder and CEO of HCD Global Consulting, which provide strategic consulting service in Healthcare, telecommunication, and manufacture industry for Chinese fortune 100 companies. Dr. Li was a project manager at Mckinsey & Company and had broad experiences of market analysis, strategy development, and project implementation for healthcare industry players. Dr. Li also worked as project manager and consultant with Booz Allen & Hamilton and A.T. Kearny.

Dr. Li received his Ph.D. in Molecular Pharmacology and Biochemistry from Harvard University, MBA from University of Chicago, and B.S. from University of Science and Technology of China.


Dr. Yi Lin

Dr. Yi Lin has fifteen years of management consulting, biomedical research, and operating experience. At McKinsey&Company and as an independent consultant, Dr. Yi Lin served China and U.S. clients in pharmaceutical/biotech, devices, industrial, telecommunications, and investment industries on strategies, organization, lean operations, sales and marketing, and M&A. He co-founded and served as COO of Eastwin Life Sciences Inc., a distributor and developer of analytical instruments and reagents. He was part of the business development team for acquisitions at Aquion Partners L.P., an industrial company specializing in water treatment systems and services.

Dr. Yi Lin holds a Ph.D. in Biomedical Sciences from Columbia University, a MBA. from University of Chicago, and a BS. in Biochemistry from Peking University. Prior to starting his Ph.D. study at Columbia, he was a research associate at Shanghai Institute of Biochemistry.


Mr. Ting Zhao

Mr. Ting Zhao was the founder of Eastwin, one of the largest medical and life sciences instruments companies with a broad distribution network in major Chinese markets. Prior to Eastwiin, Mr. Zhao was a consultant at Boston Consulting Group and Ernst & Young, LLPs healthcare practices in Boston. Mr. Zhao also worked as a Research Analyst at the Global Research & Corporate Strategy division of Searle Pharmaceuticals in Chicago.

Mr. Zhao was a Ph.D. candidate of Harvard Medical School at Harvard University. He received his MBA from University of Chicago, a M.S. degree from Tsinghua University, and a Bachelor degree from Beijing University.


Mr. Weidong Wang

Mr. Wang is specializing financial and legal advisory. He is also a visiting professor at BIMBA of Peking University. Prior to that, he was an attorney with Sidley Austin Brown & Wood. Sidley Austin Brown & Wood is an international law firm with about 1300 lawyers practicing on three continents.

The firm is one of the largest in the United States. At Sidley, he represented clients on a variety of public and private offerings of common stock, preferred stock, onvertible securities and debt securities. He also has extensive experience in venture capital, mergers & acquisitions and spin-offs. In addition, he worked closely with many technology, entrepreneurs and investors in both China and U.S. He worked at the Legislative Affairs Commission of the Standing Committee of the National Peoples Congress of the Peoples Republic of China.

Mr. Wang received his Doctor of Jurisprudence from the University of Chicago Law School. He also received a Master of Comparative Law degree from Brigham Young University Law School. He is a member of American Bar Association.


 
 
 

版权所有 © 智特医疗
津ICP备 13002568 © All Rights Reserved.